Teriparatide biosimilar - Alkem Laboratories
Alternative Names: GEMTIDELatest Information Update: 20 Jul 2026
At a glance
- Originator Alkem Laboratories
- Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Parathyroid hormone replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Osteoporosis; Postmenopausal osteoporosis
Most Recent Events
- 20 Jul 2026 Registered for Osteoporosis in India (Parenteral) prior to December 2021 (Enzene Biosciences website, July 2026)
- 17 Jul 2026 Enzene Biosciences plans to launch Teriparatide biosimilar in the World in 2025 (Enzene Biosciences pipeline, July 2026)
- 04 Dec 2025 Saya Biologics and Enzene Biosciences enters into a strategic partnership for registration, commercialization, and distribution of two biosimilars for Osteoporosis in Mexico